Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://nnpdf.org/wp-content/uploads/2023/09/Cyclo-Therapeutics-and-Applied-Molecular-Transport-Merger-Agreement-09.21.2023.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (4)
Alternatively, you can try searching for similar contracts:
